Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that
produces protective cardiovascular-renal outcomes in patients with diabetes. However, the …

Hypertension in chronic kidney disease (CKD) patients is a risk factor for end-stage renal
disease, cardiovascular events, and mortality. Thus, the prevention and appropriate …

Several large clinical trials have shown renal and cardioprotective effects of sodium–
glucose cotransporter 2 (SGLT2) inhibitors in diabetes patients, and the protective …

We have performed a systematic review of studies reporting on the renal effects of SGLT2
inhibitors in rodent models of diabetes. In 105 studies, SGLT2 inhibitors improved not only …

Highlights•SGLT2i and their clinical applications in cardio-renal complications.•SGLT2i and
Acute kidney injury: fact or fright.•Possible underlying mechanisms of SGLT2i in cardio-renal …

Diabetic nephropathy (DN), a metabolic disease, is characterized by severe systemic
metabolic disorders. A unique dietary pattern, such as intermittent fasting (IF) has shown …

Necroptosis was elevated in both tubulointerstitial and glomerular renal tissue in patients
with diabetic kidney disease (DKD), and was most pronounced on glomerulus in the stage …

Ketone bodies, including 3HBA, are endogenous products of fatty acid oxidation, and
Hmgcs2 is the first rate-limiting enzyme of ketogenesis. From database analysis and in vivo …

Sodium–glucose cotransporter inhibitors (SGLT2i) are a new class of anti-diabetic drugs that
have beneficial cardiovascular and renal effects. These drugs decrease proximal tubular …

Doxorubicin (DOX) is a frequent chemotherapeutic drug used to treat various malignant
tumors. One of the key factors that diminish its therapeutic importance is DOX-induced …